StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

INTSBullishAnalyst Target Updateanalyst
High materiality7/10

H.C. Wainwright Reiterates Buy Rating on Intensity Therapeutics, Inc. (INTS)

Aug 19, 2026, 9:01 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The analyst maintains a bullish stance with a higher target, suggesting upside potential for INTS.

AI summary

What happened, with direct paths to the underlying reporting

Analyst reiterates Buy with a higher implied path to a $7 target, signaling upside from the current price around $4.21.

  • Analyst reiterates Buy; target $7 vs. $4.21 current.

Key facts

  1. 01

    Target: $7

  2. 02

    Posted price: $4.21

  3. 03

    Analyst firm: H.C. Wainwright

  4. 04

    Analyst: Swayampakula Ramakanth

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.